These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31082764)

  • 1. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent.
    Hao T; Li Y; Fan S; Li W; Wang S; Li S; Cao R; Zhong W
    Eur J Med Chem; 2019 Aug; 175():172-186. PubMed ID: 31082764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Docking Studies of New Torin2 Analogs as Potential ATR/mTOR Kinase Inhibitors.
    Shaik A; Bhakuni R; Kirubakaran S
    Molecules; 2018 Apr; 23(5):. PubMed ID: 29695073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
    Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
    Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors.
    Lin S; Han F; Liu P; Tao J; Zhong X; Liu X; Yi C; Xu H
    Bioorg Med Chem Lett; 2014 Feb; 24(3):790-3. PubMed ID: 24433860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening.
    Ma GH; Ye Y; Zhang D; Xu X; Si P; Peng JL; Xiao YL; Cao RY; Yin YL; Chen J; Zhao LX; Zhou Y; Zhong W; Liu H; Luo XM; Chen LL; Shen X
    Eur J Med Chem; 2016 Nov; 124():981-991. PubMed ID: 27776325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and biological evaluation of anti-EV71 agents.
    Li P; Yang B; Hao F; Wang P; He H; Huang L; Zhang X; Zhang S; Peng X; Yin K; Hu J; Chen X; Gu Z; Wang L; Shen L; Hu G; Li N; Li J; Chen S; Xiao W; Wang Z; Guo Q; Chang X; Zhang L; Cai Q; Lin T
    Bioorg Med Chem Lett; 2016 Jul; 26(14):3346-3350. PubMed ID: 27234148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents.
    Sun J; Niu Y; Wang C; Zhang H; Xie B; Xu F; Jin H; Peng Y; Liang L; Xu P
    Bioorg Med Chem; 2016 Aug; 24(16):3472-82. PubMed ID: 27288186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evolution of Berberine Derivatives as a New Class of Antiviral Agents against Enterovirus 71 through the MEK/ERK Pathway and Autophagy.
    Wang YX; Yang L; Wang HQ; Zhao XQ; Liu T; Li YH; Zeng QX; Li YH; Song DQ
    Molecules; 2018 Aug; 23(8):. PubMed ID: 30127288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
    Yan W; Qing J; Mei H; Nong J; Huang J; Zhu J; Jiang H; Liu L; Zhang L; Li J
    Bioorg Med Chem Lett; 2015 Dec; 25(24):5682-6. PubMed ID: 26564266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of mTor arrests bovine oocytes in the metaphase-I stage, despite reversible inhibition of 4E-BP1 phosphorylation.
    Mayer S; Wrenzycki C; Tomek W
    Mol Reprod Dev; 2014 Apr; 81(4):363-75. PubMed ID: 24459013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor.
    Bhakuni R; Shaik A; Priya B; Kirubakaran S
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127517. PubMed ID: 32911078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
    Liu Q; Wang J; Kang SA; Thoreen CC; Hur W; Ahmed T; Sabatini DM; Gray NS
    J Med Chem; 2011 Mar; 54(5):1473-80. PubMed ID: 21322566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invitro Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in Colorectal Cancer Therapy.
    Awasthi A; Kumar P; Srikanth CV; Sahi S; Puria R
    Pathol Oncol Res; 2019 Jan; 25(1):301-309. PubMed ID: 29103204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and structure-activity relationships of PI3K/mTOR dual inhibitors from a series of 2-amino-4-methylpyrido[2,3-d]pyrimidine derivatives.
    Han F; Lin S; Liu P; Tao J; Yi C; Xu H
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4538-4541. PubMed ID: 25139570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel insights into TOR signalling in Saccharomyces cerevisiae through Torin2.
    Kumar P; Awasthi A; Nain V; Issac B; Puria R
    Gene; 2018 Aug; 669():15-27. PubMed ID: 29800736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation.
    Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
    Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.